SLC5A2 and chronic kidney disease: The Dapagliflozin and Prevention of Adverse outcomes in Chronic Kidney Disease (DAPA-CKD) trial was undertaken in participants with established CKD, who were randomized to receive the SGLT2 inhibitor, dapagliflozin or placebo on top of standard of care.